Barnwal et al. discovered that the combination therapy of mDexTA and CSF-1R inhibitor PLX-3397 effectively strengthened the infiltration of CD8+ T cells in TME, facilitating a shift from the Th1/Th2 balance to Th1 predominance, and decreasing immune-suppressor cells, such as TAMs and MDSCs in the B16-F10 murine melanoma model, thereby inhibiting tumor growth and enhancing survival rates [112]. This evidence concerns the gene CD8A and melanoma.